pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma
Janssen-Cilag International N.V
Janssen-Cilag International N.V.
Janssen-Cilag International N.V clinical programs — 67 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 161
- Drugs
- 159
- Patents
- 0
Janssen-Cilag International N.V projects
67 ClinicalTrials.gov programs sponsored by Janssen-Cilag International N.V.
Janssen-Cilag International N.V has 67 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CNTO1959ISD3001
Janssen-Cilag International N.V.
Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)
1 trial -
CNTO1959PBCRD3007
Janssen-Cilag International N.V.
Moderately to Severely Active Crohn's Disease
1 trial -
CNTO1959PSA3004
Janssen-Cilag International N.V.
Psoriatic arthritis (PsA)
1 trial -
CNTO1959PSA3005
Janssen-Cilag International N.V.
Psoriatic Arthritis
1 trial -
CNTO1959PSO3012
Janssen-Cilag International N.V.
Moderate to Severe Plaque Type Psoriasis
1 trial -
CNTO1959PUC3001
Janssen-Cilag International N.V.
Ulcerative Colitis
1 trial -
CNTO1959UCO3001
Janssen-Cilag International N.V.
Moderately to Severely Active Ulcerative Colitis
1 trial -
CNTO1959UCO3004
Janssen-Cilag International N.V.
Moderate to Severly Active Ulcerative Colitis
1 trial -
EFGARTIGIMOD ALFA, JNJ-80202135
Janssen-Cilag International N.V.
generalized myasthenia gravis
1 trial -
Enbrel solution for injection in pre-filled s... for Chronic Plaque Psoriasis
Janssen-Cilag International N.V.
Chronic Plaque Psoriasis
1 trial -
Icotrokinra, JNJ-77242113-AAC Placebo tablet
Janssen-Cilag International N.V.
Moderately to Severely Active Ulcerative Colitis
1 trial -
JNJ-54767414
Janssen-Cilag International N.V.
Precancerous form of blood cancer in the bone marrow
1 trial -
JNJ-67953964
Janssen-Cilag International N.V.
Major Depressive Disorder
1 trial -
JNJ-77242113-AAC Placebo tablet, JNJ-77242113
Janssen-Cilag International N.V.
Active Psoriatic Arthritis
1 trial -
MGT-RPGR-022
Janssen-Cilag International N.V.
X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
1 trial -
MOM-M281-006
Janssen-Cilag International N.V.
Warm Autoimmune Hemolytic Anemia
1 trial -
Matching placebo tablet, JNJ-67953964
Janssen-Cilag International N.V.
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
1 trial -
Matching placebo tablet, JNJ-67953964
Janssen-Cilag International N.V.
Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
1 trial -
Placebo Film-coated tablet, JNJ-42847922
Janssen-Cilag International N.V.
Major Depressive Disorder with Insomnia Symptoms
1 trial
Frequently asked questions
How many clinical projects does Janssen-Cilag International N.V have?
67 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.